StockData
Enliven Therapeutics, Inc. logo

Enliven Therapeutics, Inc. (ELVN) stock

ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$46.85−0.77 (-1.62%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield –

Enliven Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

No profit margin figures for Enliven Therapeutics

Enliven Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Enliven Therapeutics figures

See a number that looks wrong?